360A iodide
(Synonyms: 360A碘化物,360 A iodide) 目录号 : GC10115
360A iodide是一种G-四联体(G-quadruplex)的稳定剂,360A iodide还是有效的端粒酶(telomerase;IC50=300nM)的活性抑制剂
Cas No.:737763-37-0
Sample solution is provided at 25 µL, 10mM.
360A iodide is a G-quadruplex stabilizer and also an effective inhibitor of telomerase activity (IC₅₀=300nM)[1-2]. 360A iodide can interfere with the cell cycle and induce cancer cell death[3-4].
In vitro, treatment of human glioma cell lines T98G, CB193, and U118-MG with 360A iodide (5μM) for 7-14 days. 360A iodide significantly reduced cell viability and induced cell cycle arrest and apoptosis[5]. Treatment of ATM-deficient (ATMKD) and ATM-normal human HeLa cells with 360A iodide (5μM) for 12 hours. 360A iodide significantly induced telomere instability, including sister telomere fusion, telomere loss, and telomere doublet formation[6].
References:
[1] Granotier C, Pennarun G, Riou L, et al. Preferential binding of a G-quadruplex ligand to human chromosome ends. Nucleic Acids Res. 2005 Jul 28;33(13):4182-90.
[2] Hwang IP, Mailliet P, Hossard V, et al. Investigating the Effect of Mono- and Dimeric 360A G-Quadruplex Ligands on Telomere Stability by Single Telomere Length Analysis (STELA). Molecules. 2019 Feb 6;24(3):577.
[3] Revikumar A, Kashyap V, Palollathil A, et al. Multiple G-quadruplex binding ligand induced transcriptomic map of cancer cell lines. J Cell Commun Signal. 2022 Mar;16(1):129-135.
[4] Gauthier LR, Granotier C, Hoffschir F, et al. Rad51 and DNA-PKcs are involved in the generation of specific telomere aberrations induced by the quadruplex ligand 360A that impair mitotic cell progression and lead to cell death. Cell Mol Life Sci. 2012 Feb;69(4):629-40.
[5] Pennarun G, Granotier C, Gauthier LR, et al. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene. 2005 Apr 21;24(18):2917-28.
[6] Pennarun G, Granotier C, Hoffschir F, et al. Role of ATM in the telomere response to the G-quadruplex ligand 360A. Nucleic Acids Res. 2008 Mar;36(5):1741-54.
360A iodide是一种G-四联体(G-quadruplex)的稳定剂,360A iodide还是有效的端粒酶(telomerase;IC50=300nM)的活性抑制剂[1-2]。360A iodide可干预细胞周期,诱导癌细胞死亡[3-4]。
在体外,360A iodide (5μM)处理人脑胶质瘤细胞系T98G、CB193和U118-MG 7-14天。360A iodide显著降低细胞活力并诱导细胞周期阻滞和凋亡[5]。360A iodide(5μM)处理ATM缺陷型(ATMKD)和ATM正常的人HeLa细胞12小时。360A iodide显著诱导端粒不稳定性,包括姐妹端粒融合、端粒缺失和端粒双联体形成[6]。
| Cell experiment [1]: | |
Cell lines | Human glioma cell lines (T98G, CB193, U118-MG), ALT osteosarcoma cell line (SAOS-2), and primary normal astrocytes |
Preparation Method | Cells were maintained in DMEM supplemented with 10% fetal bovine serum, 2mM glutamine, and antibiotics at 37°C under 5% CO₂. Cells were treated with 360A iodide (5μM) for 7–14 days. |
Reaction Conditions | 5µM; 7–14 days |
Applications | 360A iodide induced dose-dependent apoptosis in telomerase-positive glioma cells and ALT-positive SAOS-2 cells, preceded by S-phase arrest, metaphase prolongation, and cytokinesis defects. |
References: | |
| Cas No. | 737763-37-0 | SDF | |
| 别名 | 360A碘化物,360 A iodide | ||
| 化学名 | (3Z,3'Z)-3,3'-((pyridine-2,6-dicarbonyl)bis(azanylylidene))bis(1-methyl-2,3-dihydroquinolin-1-ium-2-ide) dihydroiodide | ||
| Canonical SMILES | CN1=C2C=CC=CC2=C/C(C=1)=N/C(C3=NC(C(/N=C4C=C5C=CC=CC5=N(C)=C/4)=O)=CC=C3)=O.I.I | ||
| 分子式 | C27H23I2N5O2 | 分子量 | 703.31 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4218 mL | 7.1092 mL | 14.2185 mL |
| 5 mM | 284.4 μL | 1.4218 mL | 2.8437 mL |
| 10 mM | 142.2 μL | 710.9 μL | 1.4218 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
